Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Second Quallent Deal for US Adalimumab Distribution – BI follows Alvotech

May 13, 2024

On 13 May 2024, Boehringer Ingelheim (BI) announced a partnership with Cigna subsidiary Quallent Pharmaceuticals, under which Quallent will distribute high and low-concentration forms of BI’s citrate-free adalimumab biosimilar in the USA under its private label.  BI will continue to market its adalimumab products.

BI’s high concentration Cyltezo® was approved by the FDA in May 2024 and a low concentration formulation has been on the US-market since July 2023.

BI is the second Humira® biosimilar manufacturer to partner with Quallent, with Alvotech announcing last month its US partnership with Quallent to supply  Alvotech’s high-concentration interchangeable adalimumab biosimilar.